HPV status, p16 expression, clinicopathological factors, and survival were analyzed. TLR 5, 7, and 9 expression patterns differed between HPV-positive and -negative tumors, and they were statistically significantly associated with history of smoking, heavy drinking, tumor site, grade, size (T), metastasis (N), and stage. Moreover, in HPV-positive tumors the expression of TLR 5 and 7 correlated with tumor recurrence. After adjustment, among HPV-positive OPSCC patients, high TLR 5 and low TLR 7 expression were associated with poor disease-specific survival. Our results indicate that TLR 5 and 7 may have a role in the prognostication of HPV-positive OPSCC, however, further studies are needed to clarify the comprehensive role of these TLRs in OPSCC. 
Introduction
Predicting survival of oropharyngeal squamous cell carcinoma (OPSCC) has changed fundamentally over the last Abstract A large subset of oropharyngeal squamous cell carcinomas (OPSCCs) is associated with HPV infection and has better outcome than non-viral-related tumors. Various malignancies also carry a role for TLRs, key activators of inflammation and innate immunity. We examined the expression of TLRs in OPSCC, and their association with HPV status and treatment outcome. TLR 5, 7, 9, and p16 were studied by immunohistochemistry and HPV status was detected with in situ hybridization in 202 tumors of consecutively treated OPSCC patients using tissue microarray method. The relations between TLR expression and Timo Atula and Jaana Hagström equal contribution.
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Materials and methods

Patients and clinicopathological data
The patient cohort covering a 10-year period from 2000 to 2009 comprised 331 consecutive patients with oropharyngeal cancer diagnosed at the Helsinki University Hospital. Patient inclusion based on the following International Classification of Diseases 10th revision codes: C01, C02.4, C05.1, C05.2, C05.8, C05.9, C09.0, C09.1, C09.8, C09.9, C10.0, C10.2, C10.3, C10.8, and C10.9. We excluded from the analyses the patients with palliative treatment (n = 44), concurrent head and neck squamous cell carcinoma (n = 5), earlier treatment for head and neck squamous cell carcinoma (n = 11), other histology than squamous cell carcinoma (SCC) or subtype of SCC (n = 18), or tumor tissue unavailability (n = 51).
We collected clinicopathologic data from hospital registries and recorded details on patients age, sex, tumor histology, grade, TNM class, stage, primary treatment [i.e., surgery (Sx), radiotherapy (RT) and chemoradiotherapy (CRT)], tumor recurrence, treatment of recurrent disease, and status at last follow-up. Statistics Finland provided the dates and causes of death. All patients had a minimum follow-up of 3 years or until death. The Research Ethics Board at the Hospital District of Helsinki and Uusimaa approved the study design and a research permission was granted.
Of all 202 patients, 130 underwent primary Sx, and 116 received adjuvant oncological treatment (RT or CRT). No postoperative oncological therapy was provided for 14 patients because of Stage I-II disease (five cases), or patientrelated factors (nine cases). Altogether 72 patients received definitive CRT or RT, of which 11 underwent salvage Sx in the primary treatment phase (primary site only n = 1, neck only n = 7, primary site and neck n = 3). Tissue samples were collected before RT or CRT for all but two cases, where only the post treatment specimens were available for immunohistochemistry.
Immunohistochemistry
Tissue microarray blocks were prepared and immunohistochemical staining was performed as described earlier [28] . Our primary antibodies were: Monoclonal mouse antihuman TLR 5 (1:200, IMG-664A Imgenex), monoclonal rabbit anti-human TLR 7 (1:300, IMG-581A Imgenex), polyclonal rabbit anti-human TLR 9 (1:100, sc-25468 Santa Cruz Biotechnology), and monoclonal mouse anti-human p16 INK4a (9517 CINtec Histology Kit, MTM laboratories).
Immunoscore
Two researchers (J. H. and H. M.) separately scored the tissue microarray slides that were temporarily decoded to avoid their identification. In case of discordance, consensus was achieved. The positivity of TLRs 5, 7, and 9, was scored as previously described [16] . TLRs 5, 7, and 9 were scored based on the intensity of staining, because if present, most of the tumor cells stained positive. The intensity of TLRs 5 and 9 was scored as follows: none (0), mild (1), moderate (2) , and strong (3). TLR 7 mainly localized to the membrane and it was scored as follows: none (0) if no TLR 7 was observed, mild (1) if some nuclear membranes were positive, moderate (2) if all nuclear membranes and some nuclei were stained, and strong (3) if nuclear membranes and nuclei stained substantially. The tumor was regarded as p16 positive if over 70% of cells were strongly immunopositive. Whenever several tumor spots were available for analysis, the average TLR immunoscore was used, whereas p16 was stated as positive if any tumor spot was positive.
HPV in situ hybridization
The Ventana Inform HPV in situ hybridization (ISH) assay was performed with a high-risk HPV probe and iVIEW Blue detection kit in Benchmark XT series stainer (Tuscon, Arizona, USA 
Statistical analysis
We used SPSS Version 20.0 (SPSS, Inc., Chicago, IL, USA) for statistical analyses. Chi-square test with asymptotic and exact P values was used when best appropriate to calculate the statistical differences between categorical variables. TLR 7 scorings for "none" and "mild" were processed together, given the low number of TLR 7-negative tumors. The 5-year disease-specific survival (DSS) rates and recurrence-free survival (RFS) rates were calculated using the Kaplan-Meier estimate. The statistical significance in Kaplan-Meier analysis was calculated with the log-rank test.
The follow-up time in DSS analysis was defined as a time period between the last treatment day and end of follow-up or death with disease. The maximum length of follow-up was adjusted to 5 years to minimize follow-up bias. RFS time was calculated from the last treatment day to the detection of cancer recurrence either in the primary tumor site, in regional lymph nodes, or in both, or at distant sites. To present the differences between locoregional and distant RFS, in RFS analysis we censored all patients who died either of persistent OPSCC in the primary treatment phase or of other causes. The Cox proportional hazards model was used for multivariate survival analysis. Clinically relevant variables with a univariate P value less than 0.1 were included in multivariate analysis. The proportional hazards assumptions were tested with log-log curves. A two-sided P value less than 0.05 was considered statistically significant.
Results
HPV and p16
Of the total 202 tumors, 105 (52%) were HPV positive and 97 (48%) HPV negative. p16 staining revealed 117 (58%) p16-positive and 85 (42%) p16-negative tumors. The sensitivity and specificity for p16 in determining HPV status were 96.2 and 83.5%, respectively. Table 1 shows baseline characteristics of patients and expression of TLR 5, 7, and 9. The expression of TLR 5 in HPV-positive tumors was significantly lower than in HPV-negative tumors. TLR 7 was, however, eminently more expressed in HPV-positive tumors. The expression of TLR 9 was significantly lower in HPV-positive tumors than in HPV-negative tumors. Results of HPV ISH and immunohistochemical staining with antibodies for p16, and TLR 5, 7, and 9 are presented in Fig. 1 .
TLR expression and its association with patient and tumor characteristics (Table 2) TLR 5 expression was more prominent among smokers and heavy drinkers and less prominent in small (T1) tumors, in regionally advanced metastatic (N2-3) disease, in Stage III-IV diseases, in tumors arising from tonsil, and in Grade 3 tumors. TLR 7 expression was low in patients with history of smoking and heavy drinking. TLR 7 expression was, however, higher in regionally advanced metastatic (N2-3) disease and in Stage III-IV disease, in tumors arising from lateral wall and in anterior wall and in Grade 3 tumors. High TLR 9 expression was associated with current smoking, but not with any other investigated factors.
TLR expression and associations with tumor recurrence and outcome (Fig. 2; Table 3)
Low TLR 5 expression was associated with favorable 5-year locoregional RFS, but it lacked a statistically significant correlation with 5-year distant RFS. Patients with low TLR 5 expression had better DSS. The 5-year DSS rates according to TLR 5 staining categories were as follows: 0 = 88.1%, 1 = 77.1%, 2 = 70.8%, and 3 = 49.8%. TLR 7 expression had no statistically significant association with 5-year RFS.
Patients with tumors expressing TLR 7 at high levels had better DSS. The 5-year DSS rates according to TLR 7 staining categories were as follows: 1 = 52.7%, 2 = 73.2%, and 3 = 88.2%. The association between TLR 9 and 5-year RFS or DSS was absent.
TLR expression was associated with recurrence rate and DSS in patients with HPV-positive tumors ( Fig. 2 ; Table 3) HPV-positive tumors typically had low TLR 5 and 9 expression and high TLR 7 expression with good outcome. However, in patients with a HPV-positive tumor, high expression of TLR 5 and low expression of TLR 7 were associated with poor 5-year locoregional RFS. Low TLR 7 expression was also associated with poor 5-year distant RFS. Among patients with HPV-positive disease, the expression of TLR 5 and 7, but not TLR 9, influenced DSS. Patients having low TLR 5 expression had better DSS. The 5-year DSS of patients according to TLR 5 staining categories were as follows: 0 = 91.5%, 1 = 84.6%, 2 = 76.9%, and 3 = 33.3%. Patients with high TLR 7 expression had better DSS. According to TLR 7 staining categories, the 5-year DSS of patients were as follows: 1 = 33.3%, 2 = 76.7%, and 3 = 92.6%. In the group of patients with a HPV-negative tumor, low TLR 5 expression was associated with poor 5-year distant RFS. For patients with HPV-negative tumors, the TLR 5, 7, and 9 expression did not associate with DSS.
TLR 5 and 7 presented as independent prognostic factors in HPV-positive OPSCC (Table 4)
In multivariate analysis of all 202 patients, advanced regional metastasis (N2-N3) presented as an independent risk factor for poor DSS. For TLR 7 and T class, the overall P value remained non-significant, though differences were found between subgroups. TLR 7 interacted with HPV status (P = 0.027), indicating that the analysis should be stratified by HPV status. TLR 5 did not interact with HPV status (P = 0.202). Among HPV-positive OPSCC patients, high TLR 5 and low TLR 7 presented as independent factors worsening DSS. No other factors showed independent statistical significance for DSS. In HPV-negative OPSCC, TLR 5 and 7 were not independent factors for DSS. In this patient group, male gender and advanced regional metastasis (N2-3) were independent risk factors for poor DSS.
Multivariate analysis with p16 expression
In the whole study population (n = 202), the only independent factor affecting the DSS was presence of regional advanced metastases (N2-3). Similarly, as in multivariate analysis with HPV status, statistically significant hazard ratios (HRs) were found in the subgroup analyses between T classes, TLR 5 expression, and TLR 7 expression, although the overall P value remained non-significant. Although, there was statistically significant interaction neither between p16 and TLR 5 (P = 0.053), nor between p16 and TLR 7 (P = 0.244), we performed the multivariate analysis separately on all patients and patients stratified by p16 status (Supplementary Table 1 ). In the p16-positive subgroup, high TLR 5 expression was a factor affecting poor DSS, but the association with TLR 7 and DSS remained absent.
Discussion
To our knowledge, this is the first study to suggest that high expression of TLR 5 and low expression of TLR 7 might be related to poor prognosis of HPV-related OPSCC. The background for this study is our recent finding showing differences in the expression patterns of TLR 5, 7, and 9 according to tumor HPV status in OPSCC [16] . By including a larger series of tumors in this study, we confirmed our previous findings. In addition, we demonstrated that the expression patterns of TLRs 5, 7, and 9 are significantly associated with several patient and disease characteristics, most of which are also known to be linked with HPV status. These include smoking, heavy drinking, T class, N class, stage, tumor grade, and site [1, 4, 5, 7, 29] . HPV-positive and HPV-negative tumors vary in response to treatment and have markedly different prognoses. In the latest WHO classification of Head and Neck Tumours, they are classified as distinct entities [30] . Our findings showing almost an opposite TLR expression between these tumors suggest that these tumors evoke distinct immunological reactions. The fact that HPV-positive tumors respond well to non-surgical treatment, may reflect their different immunological nature. In our study, TLR 5 was more often less expressed and TLR 7 highly expressed in HPV-positive tumors. In addition, these staining patterns were noted among non-smokers and among patients who were not heavy drinkers. However, currently about half of the OPSCC recurrences develop among HPV-positive patients, along with the increasing relative rate of HPV-associated disease [8] . Our results may offer a potential prognostic biomarker in survival stratification for this growing patient group.
In various cancers, TLR 5 and 7 have been suggested to have either a prognostic role in in vivo studies [17] [18] [19] [20] [21] 27] , or a functional role in in vitro studies [31] [32] [33] [34] [35] [36] . Kauppila et al. suggested that high TLR 5 expression is associated with high rate of mortality and recurrences in oral mobile tongue SCC [17] , and Ni et al. suggested that high expression of TLR 7 could improve survival in oral SCC [21] . Although they did not study the HPV status in their series, HPV negativity in oral SCC is highly probable [37] . Therefore, our result showing that TLR 5 and 7 expression patterns are not associated with survival in HPV-negative OPSCC is in contrast with these findings. However, results for TLR 5 expression have been conflicting, as Mäkinen et al. suggested that low TLR 5 expression in oral mobile tongue SCC predicted poor prognosis [27] .
Activation of TLR 5 has been shown to cause tumor progression in gastric cancer [32] and salivary gland adenocarcinoma [31] , but in oral SCC, there is no association between TLR 5 activation and tumor progression [38] . According to a study by Burdelya et al. [39] , TLR 5 activation had radioprotective effect. Tissues being protected from radiation stress, however, were located adjacent to a tumor, and no decrease in the radiosensitivity of the tumor was observed. According to our results we can speculate that HPV-positive tumors, which are normally radiosensitive, might lose their reactivity to the treatment partly due to the upregulation of TLR 5. Table 3 TLR 5, 7, and 9 expression and 5-year locoregional and distant RFS Log-rank test was used in the statistical analysis. Death with disease and death with no evidence of disease were censored TLR 5 TLR 7 TLR 9 Stimulation of TLR 7 promotes cancer-cell survival and chemoresistance in adenocarcinoma and SCC of the lung [33, 34] . In oral cancer, however, activation of TLR 7 with imiquimod, a pharmaceutical product used clinically for basal cell carcinoma, reduces tumor growth [35] and in breast cancer enhances radiosensitivity [36] . We may only speculate if radiosensitivity of HPV-positive tumors could be associated with TLR 7 overexpression in HPV-positive OPSCC. This research thus raises the question of whether including TLR 5 signaling downregulation and TLR 7 signaling upregulation would benefit OPSCC treatment.
HPV has previously been shown to down-regulate TLR 9 in cervical cancer [40] . In addition, TLR 9 is shown to be down-regulated by other oncogenic viruses [41] [42] [43] [44] . Likewise, in our series, TLR 9 was low in HPV-positive OPSCC, even though the role of TLR 9 does not seem to be as important as that of TLR 5 and 7.
In our study, the retrospective nature of the data, and non-randomization of patients can predispose the results for unknown bias. The available details were limited especially regarding history of smoking and alcohol abuse. However, we also tested multivariate analysis with smoking details, but no change in the significance was observed. The 95% CI of TLR 5 and 7 HR in multivariate analysis of HPV-positive subgroups were broad, which is probably explained by the low number of events and patients presenting adverse TLR expression in the HPV-positive group. This may explain why multivariate analysis stratified by p16 failed to show association between DSS and TLR 7. Consequently, as the sample size remained limited, we must avoid robust conclusions concerning survival results. In two cases, specimens were unavailable before CRT, and the treatment effect on TLR expression cannot be excluded, but statistical analysis without these patients did not affect the results.
In conclusion, according to our results, the expression of TLR 5, 7, and 9 in OPSCC is associated with HPV status in the tumor tissue. Our results suggest that high TLR 5 and low TLR 7 expression might be related to poor outcome among HPV-positive OPSCC.
